Hal Barron, Chief scientific officer at GSK recently spoke about winning the hearts and minds of 10,000 R&D employees and adopting practices from acquired company, Tesaro. In Vivo covers the talk topics including how doubters are coming around amid recent successful approvals
Author: Informa Pharma Intelligence
Published: 02 September 2019
Number of pages:3
GlaxoSmithKline PLC is transforming its culture with a new emphasis on clear decision making and a focus on “smart risk taking”. Speaking at an Endpoints News UKBIO19 event in London, chief scientific officer and president of R&D, Hal Barron said this cultural transformation is already making an impact. In Vivo provides details about how a past, failed, consensus-driven approach to decision making drove his initial efforts to create a cultural change among the company’s 10,000 R&D employees so that each project would have a clear “single accountable decision-maker.” Two years later, Barron reports people noting that he didn’t just talk about a new strategy; it’s actually taking place.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.